Technical Analysis for NBIO - Nascent Biotech Inc

Grade Last Price % Change Price Change
grade F 0.1325 -30.26% -0.0575
NBIO closed down 30.26 percent on Friday, September 13, 2019, on 1 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NBIO trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -30.26%
Wide Bands Range Expansion -30.26%

Older signals for NBIO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Nascent Biotech Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The Company is engaged in the research and development of the antibodies for control of brain and pancreatic cancer in humans. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company owns the license rights to a drug candidate, pritumumab, which it is developing. The Company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. Pritumumab is a monoclonal antibody. The Company has not generated revenues.
Medicine Cancer Clinical Medicine Biopharmaceutical Drugs Treatment Of Cancer Antibodies Monoclonal Antibodies Glioblastoma Targeted Therapy Anogen Treatment Of Various Forms Of Cancer
Is NBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.77
52 Week Low 0.1
Average Volume 13,851
200-Day Moving Average 0.2269
50-Day Moving Average 0.1792
20-Day Moving Average 0.1798
10-Day Moving Average 0.1774
Average True Range 0.0242
ADX 11.01
+DI 40.5478
-DI 50.9973
Chandelier Exit (Long, 3 ATRs ) 0.1354
Chandelier Exit (Short, 3 ATRs ) 0.2051
Upper Bollinger Band 0.2226
Lower Bollinger Band 0.137
Percent B (%b) -0.05
BandWidth 47.608454
MACD Line -0.0029
MACD Signal Line -0.0005
MACD Histogram -0.0024
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1325
Resistance 3 (R3) 0.1325 0.1325 0.1325
Resistance 2 (R2) 0.1325 0.1325 0.1325 0.1325
Resistance 1 (R1) 0.1325 0.1325 0.1325 0.1325 0.1325
Pivot Point 0.1325 0.1325 0.1325 0.1325 0.1325
Support 1 (S1) 0.1325 0.1325 0.1325 0.1325 0.1325
Support 2 (S2) 0.1325 0.1325 0.1325 0.1325
Support 3 (S3) 0.1325 0.1325 0.1325
Support 4 (S4) 0.1325